CD47 and scleroderma: Because our results had shown that both hedgehog signaling and IL-6 contributed to scleroderma, we combined both immune therapies either with vismodegib (CD47/PD-L1 inhibition + vismodegib) or with the IL-6 inhibitor tocilizumab (CD47/IL-6 inhibition).